Three converging developments in the past eight months point to a trend called the Routine Data Inversion, where the assumption that controlled clinical trial datasets produce superior AI models is collapsing. A study published in 2026 in Nature Medicine demonstrated that neuroimaging AI models trained on routine health system data delivered better diagnostic performance than models trained on curated datasets. The mechanism is that models trained on diverse, variable, real-world inputs learn to generalize, while models trained on pristine trial data perform well only within conditions most clinical sites cannot replicate. This connects to research published in PLOS Medicine on dermatology AI, analyzed by Daneshjou et al., which found that AI algorithms trained on non-representative datasets showed reduced diagnostic accuracy on darker skin tones compared to lighter skin tones. The FDA updated its guidance on Real-World Evidence for medical devices in December 2025, expanding how both FDA staff and industry approach the use of such data, but the regulatory architecture was never built to handle the shift toward routine data. The operational implication is that the messiest data may be the best data for training AI models that perform on the real distribution of patients.